We can’t show the full text here under this license. Use the link below to read it at the source.
Effectiveness and safety of sodium‐glucose co‐transporter‐2 inhibitors compared with dipeptidyl peptidase‐4 inhibitors in older adults with type 2 diabetes: A nationwide population‐based study
Effectiveness and safety of two diabetes medicines in older adults with type 2 diabetes: SGLT2 inhibitors versus DPP-4 inhibitors
AI simplified
Abstract
New users of had a lower risk of hospitalization for heart failure, all-cause death, and stroke compared to .
- SGLT2 inhibitors are associated with a reduced risk of hospitalization for heart failure ( 0.86).
- All-cause mortality is lower in patients using SGLT2 inhibitors compared to those on DPP-4 inhibitors (HR 0.85).
- The risk of stroke is lower for new users of SGLT2 inhibitors (HR 0.86).
- No significant difference in the risk of myocardial infarction was observed between the two groups (HR 0.95).
- Similar rates of diabetic ketoacidosis, bone fracture, and severe hypoglycaemia were found in both groups.
- Increased risks of genital infections (HR 2.44) and urinary tract infections (HR 1.05) were noted in patients using SGLT2 inhibitors.
AI simplified
Key numbers
0.86
Lower risk of hospitalization for heart failure
Hazard Ratio for hospitalization for heart failure with vs.
0.85
Lower risk of all-cause death
Hazard Ratio for all-cause death with vs.
2.44×
Higher risk of genital infection
Hazard Ratio for genital infection with vs.